Bristol Myers Squibb’s arlo-cel meets Phase 2 multiple myeloma trial endpoints
AI Summary- Bristol Myers Squibb shared Phase 2 QUINTESSENTIAL results for experimental arlo-cel.
- Arlo-cel met primary and key secondary endpoints after four or more prior therapy lines.
- Arlo-cel treatment uses patients’ T cells and requires lymphodepleting chemotherapy before infusion.